MOUNTAIN VIEW, CA and TOKYO – Jan 28, 2008 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that the company recently signed a license agreement with Kirin Pharma Company, Limited for the exclusive worldwide rights to use Kirin’s clinical stage compound, KRN7000, formulated with a liposome. KRN7000 is a biological response modifier that [...]
REGiMMUNE today announces it has appointed Dr. Professor Robert NEGRIN as a new Scientific and Clinical Adviser to the company. Dr. Negrin is Professor of Medicine in the Division of Blood and Marrow Transplantation at Stanford University. He also holds the positions of Medical Director of the Clinical Bone Marrow Transplantation Laboratory and Division Chief [...]
Mountain View, Calif. and Tokyo, Japan – August 7, 2007 – REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today it has been awarded a grant from the Japanese Ministry of Economy, Trade and Industry (METI). REGiMMUNE received the grant under the METI-sponsored Regional New Consortium Projects/New Industry Creative-Type Technology R&D Promotion Programs, which is [...]
REGiMMUNE Establishes Broad Collaboration with RIKEN MOUNTAIN VIEW, CA and TOKYO — Mar 22, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has enter into an Intellectual Property and Industry-Academia Collaboration Program with RIKEN, a Japanese public research institute supported by the government. This arrangement provides REGiMMUNE with a number of benefits including [...]
Featured in the issue of the Biotechnology Japan. (Sorry, this article is only in Japanese.)2007
MOUNTAIN VIEW, CA and TOKYO–Feb 21, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has raised $4.2 million U.S. in a Series A venture capital financing from new and existing investors. The original lead investor NIF SMBC Ventures Co., Ltd. led the round, with the participation of existing investor Japan [...]
Mountain View, CA and Tokyo, Japan — February 1, 2007 — REGiMMUNE Corporation, a privately held biopharmaceutical company, announced today the relocation of its US offices from San Jose to Mountain View, California.
MOUNTAIN VIEW, CA and TOKYO — January 26, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today the appointment of Shirley Liu Clayton as a non-executive director. Ms. Clayton recently retired as President and Chief Executive Officer of Abmaxis, Inc., which was acquired by Merck & Co. in 2006. As Vice President and [...]
Tokyo, Japan – Nov. 29, 2006 – REGiMMUNE Corporation announced today the appointment of Mr. Hiroki NARITA, the Deputy General Manager, Investment Group, NIF SMBC Ventures, Japan, to its Board of Directors. Mr. Narita has participated in the investment of approximately $40 million in 11 biotechnology companies, including MediciNova, Inc. and LTT Bio-Pharma Co., Ltd. [...]
Tokyo, Japan – Nov. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the opening of a new subsidiary in the United States in San Jose, California. “REGiMMUNE is planning to enter clinical studies in the US in 2009, for autoimmune diseases such as GvHD, SLE and MS. To achieve this plan, we [...]
Dr. ISHII, a member of our Scientific Advisory Board, and REGiMMUNE were featured in issue of the publication Biotechnology Japan.
Tokyo, Japan, – Sept. 20, 2006 – REGiMMUNE Corporation announced today the appointment of Dr. Yasuyuki ISHII, Team Leader of the Laboratory for Vaccine Design at the RIKEN Research Center for Allergy and Immunology (RCAI), “We are delighted to have a world-renowned researcher with expertise in immunology and molecular biology providing us with advice to strengthen REGiMMUNE’s [...]
Tokyo, Japan – Sept. 1, 2006 – REGiMMUNE Corporation has relocated its headquarters from Toranomon, Tokyo to: 3-12-5 Shibaura, Ishizaka Bldg. 6F Minato-ku, Tokyo 108-0023 Japan phone +81-3-3456-0820
Tokyo, Japan –Aug. 15, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the closing of the Company’s Seed Round Financing, adding $1.6 million in additional new equity. New venture capital investors NIF SMBC Ventures, Nikko AntFactory and Japan Asia Investment Company, joined existing shareholders.